Celldex Therapeutics CLDX
$27.42 −$0.54 (-1.93%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.40 -0.07%
Open$27.01
Prev close$27.96
Day range$26.64 – $28.43
Volume1.72M
Market cap$2.15B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$82.25M-11.7% YoY
Net profit-$75.56M-12.7% YoY
Diluted EPS-$0.96+5.0% YoY
Free cash flow-$66.70M-35.9% YoY
Operating cash flow-$65.04M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-211,684.8%
Net margin-195,608.9%
Return on equity-49.5%
Return on assets-45.1%
Return on invested capital-49.0%
Current ratio10.97
Liabilities / assets10.0%
Cash & investments$650.32M
Total debt$8.43M
Net cash (debt)$641.89M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $22,000.00 | $15,000.00 | $1.55M | $121,000.00 |
| Total Operating Revenue | $0.00 | $22,000.00 | $15,000.00 | $1.55M | $121,000.00 |
| Operating Expense | $82.25M | $80.65M | $84.45M | $288.91M | $87.27M |
| Selling and Admin Expenses | $14.84M | $13.10M | $11.45M | $43.84M | $11.94M |
| -General & Admin Expense | $14.84M | $13.10M | $11.45M | $43.84M | $11.94M |
| Research & Development | $67.41M | $67.54M | $73.00M | $245.07M | $75.33M |
| Operating Profit | -$82.25M | -$80.62M | -$84.44M | -$287.37M | -$87.15M |
| Other Income (Expense) | $6.69M | $7.12M | $5.75M | $28.61M | $5.84M |
| Gain on Sale of Security | $6.69M | $7.12M | $5.75M | $28.61M | $5.84M |
| Pretax Profit | -$75.56M | -$73.50M | -$78.69M | -$258.76M | -$81.32M |
| Net Profit | -$75.56M | -$73.50M | -$78.69M | -$258.76M | -$81.32M |
| Profit from Continuing Operations | -$75.56M | -$73.50M | -$78.69M | -$258.76M | -$81.32M |
| Net Income to Parent Company | -$75.56M | -$73.50M | -$78.69M | -$258.76M | -$81.32M |
| Net Income to Common Stockholders | -$75.56M | -$73.50M | -$78.69M | -$258.76M | -$81.32M |
| Basic EPS | -$0.96 | -$0.94 | -$1.18 | -$3.90 | -$1.22 |
| Diluted EPS | -$0.96 | -$0.94 | -$1.18 | -$3.90 | -$1.22 |
| Special Income (Charges) | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $721.53M | $782.35M | $511.25M | $582.98M | $582.98M |
| Total Current Assets | $663.74M | $724.93M | $459.22M | $534.66M | $534.66M |
| Cash and Cash Equivalents & Short-Term Investments | $650.32M | $717.59M | $451.46M | $518.57M | $518.57M |
| -Cash and Cash Equivalents | $26.95M | $47.45M | $35.73M | $28.87M | $28.87M |
| -Short Term Investments | $623.37M | $670.13M | $415.73M | $489.70M | $489.70M |
| Receivables | $355,000.00 | $230,000.00 | $230,000.00 | $2.02M | $2.02M |
| -Accounts Receivable | $355,000.00 | $230,000.00 | $230,000.00 | $2.02M | $2.02M |
| Other Current Assets | $13.06M | $7.11M | $7.53M | $14.08M | $14.08M |
| Total Non-Current Assets | $57.80M | $57.42M | $52.03M | $48.32M | $48.32M |
| Net PPE | $20.92M | $14.79M | $9.41M | $7.77M | $7.77M |
| -Gross PPE | $20.92M | $14.79M | $9.41M | $31.68M | $31.68M |
| Non-Current Prepaid Assets | $9.10M | $14.80M | $14.80M | $13.36M | $13.36M |
| Goodwill and Other Intangible Assets | $27.19M | $27.19M | $27.19M | $27.19M | $27.19M |
| -Other Intangible Assets | $27.19M | $27.19M | $27.19M | $27.19M | $27.19M |
| Other Non-Current Assets | $586,000.00 | $634,000.00 | $634,000.00 | – | – |
| Total Liabilities | $72.06M | $67.79M | $55.03M | $55.82M | $55.82M |
| Total Current Liabilities | $60.52M | $61.33M | $51.47M | $50.99M | $50.99M |
| Payables | $11.24M | $14.68M | $10.36M | $1.18M | $1.18M |
| -Accounts Payable | $11.24M | $14.68M | $10.36M | $1.18M | $1.18M |
| Current Accrued Expenses | $46.61M | $43.86M | $38.42M | $47.03M | $47.03M |
| Short-Term Debt and Capital Lease Obligation | $1.44M | $1.56M | $1.47M | $1.55M | $1.55M |
| -Current Capital Lease Obligation | $1.44M | $1.56M | $1.47M | $1.55M | $1.55M |
| Other Current Liabilities | $1.23M | $1.23M | $1.23M | $1.23M | $1.23M |
| Total Non-Current Liabilities | $11.55M | $6.46M | $3.56M | $4.83M | $4.83M |
| Long Term Debt and Capital Lease Obligation | $8.43M | $3.35M | $443,000.00 | $784,000.00 | $784,000.00 |
| -Long Term Capital Lease Obligation | $8.43M | $3.35M | $443,000.00 | $784,000.00 | $784,000.00 |
| Other Non-Current Liabilities | $3.11M | $3.11M | $3.11M | $4.04M | $4.04M |
| Total Equity | $649.47M | $714.56M | $456.23M | $527.17M | $527.17M |
| Stockholders' Equity | $649.47M | $714.56M | $456.23M | $527.17M | $527.17M |
| Capital Stock | $79,000.00 | $79,000.00 | $67,000.00 | $67,000.00 | $67,000.00 |
| -Common Stock | $79,000.00 | $79,000.00 | $67,000.00 | $67,000.00 | $67,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $2.69B | $2.68B | $2.35B | $2.34B | $2.34B |
| Retained Earnings | -$2.04B | -$1.97B | -$1.89B | -$1.81B | -$1.81B |
| Gains/Losses Not Affecting Retained Earnings | -$329,000.00 | $1.30M | $2.52M | $3.63M | $3.63M |
| -Accumulated Depreciation | – | – | – | -$23.90M | -$23.90M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$65.04M | -$57.41M | -$65.59M | -$210.95M | -$63.94M |
| Net cash flow from continuing operations | -$65.04M | -$57.41M | -$65.59M | -$210.95M | -$63.94M |
| Net Income from Continuing Operations | -$75.56M | -$73.50M | -$78.69M | -$258.76M | -$81.32M |
| Gain/Loss from Continuing Operations | $47,000.00 | $1,000.00 | $3,000.00 | $12,000.00 | $0.00 |
| Depreciation & Depletion & Amortization | $1.16M | $902,000.00 | $854,000.00 | $3.38M | $816,000.00 |
| Change in Working Capital | -$872,000.00 | $8.48M | $4.35M | $14.06M | $8.53M |
| -Change in Receivables | -$125,000.00 | $0.00 | $1.79M | -$1.32M | -$1.93M |
| -Change in Prepaid Assets | -$5.11M | -$1.17M | $6.28M | $8.71M | $8.47M |
| -Change in Payables and Accrued Expense | -$823,000.00 | $10.14M | -$287,000.00 | $11.03M | $4.60M |
| -Change in Other Current Assets | $5.75M | $0.00 | -$2.08M | -$3.61M | -$3.99M |
| -Change in Other Current Liabilities | -$567,000.00 | -$490,000.00 | -$1.36M | -$753,000.00 | $1.38M |
| Net cash flow from investing | $43.42M | -$255.52M | $72.12M | $209.07M | $55.43M |
| Net Cash Flow from Continuing Investing Activities | $43.42M | -$255.52M | $72.12M | $209.07M | $55.43M |
| Net PPE Purchase and Sale | -$1.67M | -$3.18M | -$1.64M | -$2.71M | -$1.28M |
| Net Investment Purchase and Sale | $45.09M | -$252.34M | $73.76M | $211.79M | $56.71M |
| Financing Cash Flow | $1.12M | $324.66M | $327,000.00 | $2.39M | $1.35M |
| Net Cash Flow from Continuing Financing Activities | $1.12M | $324.66M | $327,000.00 | $2.39M | $1.35M |
| Net Common Stock Issuance | $0.00 | $323.83M | $0.00 | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $1.12M | $825,000.00 | $327,000.00 | $2.39M | $1.35M |
| Ending Cash Balance | $26.95M | $47.45M | $35.73M | $28.87M | $28.87M |
| Net Change in Cash | -$20.50M | $11.73M | $6.86M | $515,000.00 | -$7.17M |
| Beginning Cash Balance | $47.45M | $35.73M | $28.87M | $28.36M | $36.04M |
| Free Cash Flow | -$66.70M | -$60.59M | -$67.23M | -$213.66M | -$65.22M |
No comments yet — be the first to weigh in on CLDX.
Sign in to join the discussion.